- Home
- Publications
- Publication Search
- Publication Details
Title
PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s
Authors
Keywords
PPAR gamma, PGC-1 alpha, Parkinson’s disease, Neuroprotection
Journal
NEUROCHEMICAL RESEARCH
Volume 40, Issue 2, Pages 308-316
Publisher
Springer Nature
Online
2014-07-09
DOI
10.1007/s11064-014-1377-0
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PPARγ activation rescues mitochondrial function from inhibition of complex I and loss of PINK1
- (2014) Juan Carlos Corona et al. EXPERIMENTAL NEUROLOGY
- Neuroprotective Properties of a Novel Non-Thiazoledinedione Partial PPAR-γAgonist against MPTP
- (2013) Christine R. Swanson et al. PPAR Research
- PGC-1α: a master gene that is hard to master
- (2012) Dan Lindholm et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Pharmacological manipulation of peroxisome proliferator-activated receptor γ (PPARγ) reveals a role for anti-oxidant protection in a model of Parkinson's disease
- (2012) Heather L. Martin et al. EXPERIMENTAL NEUROLOGY
- Sustained expression of PGC-1 in the rat nigrostriatal system selectively impairs dopaminergic function
- (2012) C. Ciron et al. HUMAN MOLECULAR GENETICS
- Differential susceptibility to the PPAR-γ agonist pioglitazone in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 6-hydroxydopamine rodent models of Parkinson's disease
- (2012) C. Laloux et al. PHARMACOLOGICAL RESEARCH
- Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats
- (2012) Eun Young Lee et al. TOXICOLOGY LETTERS
- Effects of pioglitazone and retinoic acid in a rotenone model of Parkinson's disease
- (2011) Gokhan K. Ulusoy et al. BRAIN RESEARCH BULLETIN
- PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
- (2011) Joo-Ho Shin et al. CELL
- Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson’s disease
- (2011) Giuseppa Mudò et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- The PPAR-γ agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
- (2011) Christine R Swanson et al. Journal of Neuroinflammation
- Mitochondrial Parkin Recruitment Is Impaired in Neurons Derived from Mutant PINK1 Induced Pluripotent Stem Cells
- (2011) P. Seibler et al. JOURNAL OF NEUROSCIENCE
- Telomere dysfunction induces metabolic and mitochondrial compromise
- (2011) Ergün Sahin et al. NATURE
- Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: new evidences on neuroprotection in a progressive Parkinson's disease model
- (2011) A.R. Carta et al. NEUROSCIENCE
- Double antioxidant activities of rosiglitazone against high glucose-induced oxidative stress in hepatocyte
- (2011) Xin Wang et al. TOXICOLOGY IN VITRO
- Reduced expression of peroxisome-proliferator activated receptor gamma coactivator-1α enhances α-synuclein oligomerization and down regulates AKT/GSK3β signaling pathway in human neuronal cells that inducibly express α-synuclein
- (2010) Abdul Shukkur Ebrahim et al. NEUROSCIENCE LETTERS
- PGC-1 , A Potential Therapeutic Target for Early Intervention in Parkinson's Disease
- (2010) B. Zheng et al. Science Translational Medicine
- PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson’s disease
- (2009) Nicoletta Schintu et al. EUROPEAN JOURNAL OF NEUROSCIENCE
- PGC-1α and PGC-1β Regulate Mitochondrial Density in Neurons
- (2009) Przemyslaw Wareski et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- SUMOylation Attenuates the Function of PGC-1α
- (2009) Miia M. Rytinki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nrf2 activators provide neuroprotection against 6-hydroxydopamine toxicity in rat organotypic nigrostriatal cocultures
- (2009) Aubrey Siebert et al. JOURNAL OF NEUROSCIENCE RESEARCH
- Nrf2 signaling and cell survival
- (2009) Suryakant K. Niture et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- The PPARγ agonist pioglitazone is effective in the MPTP mouse model of Parkinson's disease through inhibition of monoamine oxidase B
- (2008) L P Quinn et al. BRITISH JOURNAL OF PHARMACOLOGY
- Emerging pathways in genetic Parkinson’s disease: Autosomal-recessive genes in Parkinson’s disease - a common pathway?
- (2008) Julia C. Fitzgerald et al. FEBS Journal
- PPAR: a therapeutic target in Parkinsons disease
- (2008) Rajnish K. Chaturvedi et al. JOURNAL OF NEUROCHEMISTRY
- Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K/Akt
- (2008) Bin Xing et al. Journal of Neuroinflammation
- Complete Rescue of Cerebrovascular Function in Aged Alzheimer's Disease Transgenic Mice by Antioxidants and Pioglitazone, a Peroxisome Proliferator-Activated Receptor Agonist
- (2008) N. Nicolakakis et al. JOURNAL OF NEUROSCIENCE
- Mitochondria in the aetiology and pathogenesis of Parkinson's disease
- (2008) Anthony HV Schapira LANCET NEUROLOGY
- PPARγ agonists as therapeutics for the treatment of Alzheimer’s disease
- (2008) Gary Landreth et al. Neurotherapeutics
- Review of the expression of peroxisome proliferator-activated receptors alpha (PPARα), beta (PPARβ), and gamma (PPARγ) in rodent and human development
- (2008) Barbara D. Abbott REPRODUCTIVE TOXICOLOGY
- Neurobiology and treatment of Parkinson's disease
- (2008) Anthony H.V. Schapira TRENDS IN PHARMACOLOGICAL SCIENCES
- Regulation of Glial Cell Functions by PPAR- Natural and Synthetic Agonists
- (2008) Antonietta Bernardo et al. PPAR Research
- Interleukin-4 mediates the neuroprotective effects of rosiglitazone in the aged brain
- (2007) David J. Loane et al. NEUROBIOLOGY OF AGING
- Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague–Dawley rats
- (2007) Randy L. Hunter et al. NEUROSCIENCE LETTERS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started